VolitionRx Ltd. has entered into a co-marketing and services agreement with Hologic Diagenode, part of Hologic Inc., to promote Volition's Nu.Q Discover service. This program offers drug developers and scientists a suite of assays for rapid epigenetic profiling across disease model development, preclinical testing, and clinical studies. The partnership represents a strategic move to expand customer access to proprietary epigenetic testing technology in the pharmaco-epigenetics market.
Dr. Jasmine Kway, Chief Executive Officer of Singapore Volition, described the agreement as a significant milestone for the Nu.Q Discover program. The collaboration is expected to greatly expand customer access to Volition's proprietary Nu.Q Discover assays, which have an estimated total addressable market of $200 million annually. This partnership strengthens Volition's position in the growing pharmaco-epigenetics market while supporting revenue growth through expanded service offerings.
Raphael Werding, Head of Life Sciences at Hologic, expressed enthusiasm for adding Nu.Q Discover to Hologic's service portfolio. Hologic brings extensive experience not only in oncology but also in other disease areas including cardiovascular, neurodegenerative, and immunology research. The company believes nucleosome quantification can provide additional valuable biological insights to its biotech, pharmaceutical, and academic clients across multiple disease research areas.
Under the terms of the agreement, Hologic will co-market Nu.Q Discover with its existing customer base for an initial one-year term. The arrangement includes potential for expansion into an exclusive provider relationship subject to further terms and conditions. This structured approach allows both companies to evaluate market response while maintaining flexibility for future collaboration enhancements.
The partnership between Volition and Hologic represents an important development in the epigenetics research landscape. Epigenetic profiling has emerged as a critical tool in understanding disease mechanisms and developing targeted therapies. The Nu.Q Discover service's ability to provide rapid epigenetic profiling across multiple research phases could accelerate drug development timelines and improve research efficiency for pharmaceutical companies and academic institutions.
For more information about Volition, visit https://www.Volition.com. Additional details about InvestorWire services can be found at https://www.InvestorWire.com. The full terms of use and disclaimers applicable to content provided by InvestorWire are available at https://www.InvestorWire.com/Disclaimer.
